Statera BioPharma Total Revenue

The latest total revenue for STAB is $3.7M as of September 2022. That compares with $240K in the prior-year period — up 1459.1% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Statera BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, STAB's total revenue moved from $240K to $3.7M — a 1459.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Statera BioPharma's operating scale or balance-sheet position.

Against Healthcare companies, STAB currently prints $3.7M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Statera BioPharma's growth, margins, and balance sheet.

A total revenue figure of $3.7M for STAB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting STAB's total revenue ($3.7M), review year-over-year change from $240K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.